Constellation Pharmaceuticals was founded in 2008 by academic leaders in the field and has assembled a team of seasoned scientific, medical, and business leaders to accomplish its goal of translating stellar science into breakthrough medicines. The company seamlessly integrates a unique target validation platform, expertise in structural biology, automated screening technologies, proprietary biochemical, cellular, and biophysical assays, medicinal chemistry capabilities, and experience in clinical drug development.

Our Investors

The Column Group

The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics.

Third Rock Ventures

Third Rock Ventures discovers, launches and builds great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality – providing the best opportunity to make a dramatic difference in patients’ lives.


Venrock helps entrepreneurs build some of the world’s most disruptive, successful companies. We partner with entrepreneurs who have grand ambitions – who want to tackle big, hard problems that most think not possible. Our collaboration – engagement, network, passion and experience – gives entrepreneurs the unfair advantage needed to win, and win big.


SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Celebrating its 30th anniversary in 2015, SR One has invested $1B in more than 170 companies, and its current portfolio includes 40 private and public companies. Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.

Altitude Life Science Ventures

Altitude Life Science Ventures philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in those markets to build defensible, strong, and long-term businesses.